Minimally-invasive therapies in localized prostate cancer offer the potential to reduce side effects and the healthcare burden/costs associated with radical modalities such as surgery or radiotherapy. As radical treatments carry significant perioperative morbidity (wound infection, haemorrhage, hospital stay), potentially life-long side effects (such as incontinence, erectile dysfunction, rectal toxicity), and fail to cure many men, ablative therapies that reduce treatment burden while retaining acceptable cancer control have increasingly become areas of evaluation. This chapter reviews the role of these approaches and the therapeutic dilemma that men with localized low volume prostate cancer currently face as in the context of novel therapies which aim to find a middle ground—tissue-preserving focal therapy—that follows the paradigm of almost all other solid organ cancers.
The Role of the Magnetic Resonance Imaging for the Accurate Management of Focal Therapy with High-Intensity Focused Ultrasound for the Localized Prostate Cancer
